Research Papers:
Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2175 views | HTML 4077 views | ?
Abstract
Yun-Kai Zhang1,*, Hengyuan Zhang2,*, Guan-Nan Zhang1, Yi-Jun Wang1, Rishil J. Kathawala1, Rui Si1, Bhargav A. Patel1, Jinyi Xu2, Zhe-Sheng Chen1
1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA
2Department of Medicinal Chemistry and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China
*These authors have contributed equally to this work
Correspondence to:
Zhe-Sheng Chen, e-mail: [email protected]
Jin-Yi Xu, e-mail: [email protected]
Keywords: ABC transporter, multidrug resistance, ABCB1, ginsenoside, ocotillol-type triterpenoid derivatives
Received: May 05, 2015 Accepted: June 22, 2015 Published: July 04, 2015
ABSTRACT
Overexpression of ATP-Binding Cassette transporters leads to multidrug resistance in cancer cells and results in the failure of chemotherapy. In this in-vitro study, we investigated whether or not (20S, 24R/S)-epoxy-12β, 25-dihydroxy-dommarane-3β-amine (ORA and OSA), a pair of semi-synthetic ocotillol analogue epimers, could inhibit the ABCB1 transporter. ORA (1 μM and 3 μM) significantly reversed the resistance to paclitaxel and vincristine in ABCB1-overexpressing SW620/Ad300 and HEK/ABCB1 cells, whereas OSA had no significant effects. In addition, ORA (3 μM) significantly increased the intracellular accumulation of [3H]-paclitaxel by suppressing the efflux function of ABCB1. Meanwhile, both ORA (3 μM) and OSA (3 μM) did not significantly alter the expression level or the subcellular location of ABCB1 protein. Moreover, the ABCB1 ATPase study suggested that ORA had a stronger stimulatory effect on the ATPase activity than OSA. ORA also exhibited a higher docking score as compared with OSA inside transmembrane domain of ABCB1. Overall, we concluded that ORA reverse ABCB1-mediated MDR by competitively inhibiting the ABCB1 drug efflux function.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4493